louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01489930: Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults
Official title: Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sarcopenia
Keywords: Exercise
Aging
Sarcopenia
Mitochondria
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2011-12-12
Enrollment: 67
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Loss of skeletal muscle strength and skeletal muscle mass occurs with of aging. This are-related decline in skeletal muscle mass and skeletal muscle strength is a major underlying factor contributing to many of the metabolic disorders and frailty of the investigators rapidly expanding aging population. Endurance (aerobic) and resistance exercise training programs have been shown to effectively reverse the age-related decline in metabolic and contractile muscle functions. The investigators will measure synthesis rates of individual muscle proteins in 36 each of young (18-30 yrs) and 36 older (\> 65 yrs) people to determine their response to 8 weeks each of endurance, resistance, combined endurance and resistance training, or placebo exercise training.

Hypotheses.

1. to measure fractional synthesis rates of multiple muscle proteins and identify those that are enhanced by an endurance exercise program
2. to determine whether changes in protein synthesis in response to endurance exercise programs are dependent on age
3. to measure fractional muscle synthesis rates of multiple muscle proteins and to identify those that are enhanced by a resistance exercise program
4. to determine whether changes in protein synthesis in response to resistance exercise programs are dependent on age


Eligibility criteria: Inclusion Criteria:

* Healthy
* 18 to 30 or \>65 years
* Males and Females

Exclusion Criteria:

* Regular Exercise Program
* Smoking
* Cardiometabolic Disease (diabetes, cardiovascular disease, thyroid disorders)
* Drugs known to impair metabolic function (beta blockers, steroids)
* Allergies to lidocaine
* Physical disability that precludes exercise

Primary outcomes:
measure: Skeletal Muscle Protein Synthesis
timeFrame: Measured at week 0 (baseline) and week 8
Secondary outcomes:
measure: Mitochondrial Function
timeFrame: Measured at week 0 (baseline) and week 8
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: K. Sreekumaran Nair, MD, PD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Irving BA, Lanza IR, Henderson GC, Rao RR, Spiegelman BM, Nair KS. Combined training enhances skeletal muscle mitochondrial oxidative capacity independent of age. J Clin Endocrinol Metab. 2015 Apr;100(4):1654-63. doi: 10.1210/jc.2014-3081. Epub 2015 Jan 19.
Clinical trial NCT02312830: Belgian Cross-sectional Allogeneic Transplant Survivor Study
Official title: Belgian Cross-sectional Allogeneic Transplant Survivor Study
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation, Allogeneic
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2014-12-09
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adult patients transplanted in UZ Leuven between 1992 and 2012 with an allogeneic donor (i.e. being at least 2 years post-Tx) - Hematopoietic Stem Cell Transplantation, presenting for a standard medical check up

Brief summary: With the increasing successful use of allogeneic hematopoietic stem cell transplantation (HSCT) to cure advanced hematological disease, it becomes essential to evaluate the long-term effects of such a drastic treatment.

This study investigates the prevalence of several demographic, psychosocial and behavioral aspects of survivorship after an allogeneic transplantation. Income, return to work, social isolation, pain, medication adherence, influenza vaccination status, alcohol use, smoking habits, drug use, healthy diet, prevention of UV exposure, physical activity, functional status/Quality of life (QoL), couple life/sexual function, depression, anxiety, spirituality and resilience will be studied.

Detailed description: This is a cross sectional study, where participants are interviewed and fill in a self reported survey. The interview and survey are only taken once. It is non interventional because the patients only give us extra information, which is not usually recorded in our medical records.

Eligibility criteria: Inclusion Criteria:

* Ability to read and write in Dutch
* Age above 18 years at time of transplant
* Transplanted in UZ Leuven between 1992 and 2012 with an allogeneic donor (i.e. being at least 2 years post-Tx)
* Presenting for a periodic health check in UZLEUVEN from November 15th, 2014 to November 15th 2016
* Willing to provide oral and written consent

Exclusion Criteria:

* Unable to communicate fluently in Dutch
* Presenting with major visual, hearing, cognitive or psychiatric conditions precluding participation
* Presenting with relapse or other major illness, with less than 6 months expected survival
* Hospitalized for a life-threatening condition

Primary outcomes:
measure: composite outcome: prevalence of several demographic, psychosocial and behavioral aspects of survivorship after an allogeneic transplantation
timeFrame: The interview/survey will happen once per patient and will be offered to all transplant survivors (minimum 2 years post transplant) coming to the clinic between Nov 2014-Nov 2016. No follow up included.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01120730: Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury
Official title: Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Survival
Renal Failure
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2010-05-11
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: HES 200/0.5 10% is equal to ringers lactat solution.

Detailed description: 30 Patients were enrolled to the study, either to the hyperoncotic HES 200/0.5 (10%) group or to the crystalloids only group. After a treatment protocol of 72 hours we collected data about complications like pulmonary failure and abdominal compartment syndrome. Furthermore, we addressed the question of incidence of mortality and renal failure.

Eligibility criteria: Inclusion Criteria:

* All burn victims with burned surface area bigger than 20%

Exclusion Criteria:

* Pregnancy

Primary outcomes:
measure: Intensive care unit mortality
timeFrame: 28 days
Secondary outcomes:
measure: fluid amount during the first 72 hours
timeFrame: 28 days
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich
Study officials:
affiliation: University of Zurich
name: Markus Béchir, md
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bechir M, Puhan MA, Neff SB, Guggenheim M, Wedler V, Stover JF, Stocker R, Neff TA. Early fluid resuscitation with hyperoncotic hydroxyethyl starch 200/0.5 (10%) in severe burn injury. Crit Care. 2010;14(3):R123. doi: 10.1186/cc9086. Epub 2010 Jun 28.
Clinical trial NCT04503330: Buccal Mucosal Graft for the Repair of Iatrogenic Pelviureteric Junction Obstruction or Ureteric Stricture.
Official title: Using Buccal Mucosal Graft as an Augmention Graft for Complex Cases of Iatrogenic Pelviureteric Junction Obstruction and Long Segment Ureteric Stricture Disease.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pelvi Ureteric Junction Obstruction or Ureteral Stricture
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-08-07
Enrollment: 20
Sex: ALL
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: 20 patients with iatrogenic pelviureteric junction obstruction or ureteric stricture disease
Primary purpose: TREATMENT

Brief summary: Prospective study to evaluate the safety and efficacy of using buccal mucosal graft for repairing complex cases of iatrogenic pelvi ureteric junction obstruction and long segment ureteric stricture disease.

Detailed description: A graft of buccal mucosa will be used to augment either the narrow unhealthy pelviureteric junction or a narrow long segment of the ureter.

after freeing the narrowed part, a posterior incision will be made in the ureter or renal pelvis then the graft will be implanted on the psoas muscle using interrupted sutures in a position the allows easy anastomosis to the ureter or renal pelvis.

Alternatively a lateral incision in the renal pelvis or the ureter may be done for the graft anastomosis and then surrounded with omenal flap to ensure a good blood supply for the graft.

Eligibility criteria: Inclusion Criteria:

- any patient with iatrogenic pelviureteric junction obstruction or long segment ureteric stricture

Exclusion Criteria:

* elderly patients unfit for general anaesthesia.

Primary outcomes:
measure: Number of Participants with patent renal pelvis and ureter after surgery.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06610630: Research on the Application of AI Image Recognition-Based Smartphone Apps in Personalized Bowel Preparation
Official title: Research on the Application of AI Image Recognition-Based Smartphone Apps in Personalized Bowel Preparation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Polyps
Keywords: Colonoscopy
bowel preparation
artificial intelligence
smartphone
BBPS score
Lead sponsor: The First Affiliated Hospital of Zhengzhou University
Sponsor class: OTHER
First posted: 2024-09-24
Enrollment: 513
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Colorectal cancer, as one of the most common malignant tumors of the digestive system, has a high incidence and mortality rate worldwide. High-quality colonoscopy is essential for the early detection and prevention of colorectal cancer and is key to improving the survival rates of patients. However, traditional colonoscopy faces numerous challenges in bowel preparation, such as inadequate preparation and a lack of personalized cleansing approaches. Therefore, it is particularly important to develop timely and efficient individualized bowel preparation methods. Artificial intelligence, especially deep learning technologies, has shown great potential in the medical field. This study aims to leverage the advantages of artificial intelligence to optimize the bowel preparation process before colonoscopy, creating a personalized bowel preparation plan that effectively improves the efficacy of colorectal cancer screening and diagnosis.


Eligibility criteria: Inclusion Criteria:

* Patients who underwent painless colonoscopy at the Digestive Endoscopy Center of the First Affiliated Hospital of Zhengzhou University and signed the informed consent for the clinical trial.

Individuals who use smartphones.

Exclusion Criteria:

* Patients with contraindications for colonoscopy. Individuals in whom successful cecal intubation could not be achieved.

Primary outcomes:
measure: Boston Bowel Preparation Scale
timeFrame: During Colonoscopy
measure: Dosage of Bowel Cleansing Agents
timeFrame: During Bowel Preparation Before Colonoscopy
Secondary outcomes:
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: The First Affiliated Hospital of Zhengzhou University
state: Henan
Study officials:
References:
Clinical trial NCT04193930: Different Protocols in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles
Official title: Soft Versus Conventional Protocol in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles for Poor Responders
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: ART
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-12-10
Enrollment: 0
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: During assisted reproduction technology treatments like in vitro fertilization, some patients give a poor ovarian response to controlled ovarian hyperstimulation. The European Society of Human Reproduction and Embryology consensus defined poor response to ovarian stimulation during in vitro fertilization with Bologna criteria.

Bologna criteria: At least two of the following three features must be present:

(i) Advanced maternal age (≥40 years). (ii) Previous Poor responders (≤3 oocytes with a conventional stimulation protocol).

(iii) An abnormal ovarian reserve test Most controlled ovarian hyperstimulation regimens currently used for expected poor responders are based on using a high daily dose (300- 450 IU/day) of exogenous gonadotropins. Giving a high gonadotropin dose obviously increases the cost of in vitro fertilization, a consequence that would be acceptable if paralleled by an improvement in in vitro fertilization outcome. Unfortunately, however, the available data suggest that increasing the daily gonadotropins dose may increase the number of retrieved oocytes, but not the final success rate of in vitro fertilization.


Eligibility criteria: Inclusion Criteria:

* Advanced maternal age (≥40 years) .
* Previous Poor responders (≤3 oocytes with a conventional stimulation protocol).
* An abnormal ovarian reserve tests

Exclusion Criteria:

* Hyper or Normal responders patients.
* Endocrine or metabolic diseases like hyperprolactinoma, hypothyroidism,...etc
* Patients with a severe male factor abnormality. 4-Patients with systemic disease such as chronic renal disease, chronic liver disease, etc

Primary outcomes:
measure: Total gonadotrophins dose
timeFrame: 14 days
Secondary outcomes:
measure: Duration of ovarian stimulation
timeFrame: 14 days
measure: Endometrial thickness
timeFrame: 14 days
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Women Health Hospital - Assiut university
Study officials:
References:
Clinical trial NCT00984230: A New Adaptive Feeding Plan for Newborns
Official title: A New Adaptive Feeding Plan for Newborns: Effects on Gut Maturity and Gut Microbiota
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infant Nutrition
Keywords: Infant Formula
Gut
Lead sponsor: Société des Produits Nestlé (SPN)
Sponsor class: INDUSTRY
First posted: 2009-09-25
Enrollment: 186
Sex: ALL
Minimum age (years): 1
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this clinical trial is to identify the infant formula(s) for which the investigators get the closest gut maturation index compared to the one they get with breastfed babies.


Eligibility criteria: Inclusion Criteria:

* Healthy newborn infant
* Full term infant (≥ 37 weeks gestation; \< 42 weeks gestation)
* Birth weight from 2500g to 4500g
* For the formula-fed groups: babies whose mothers elected not to breastfeed at all
* For the breastfed group: babies whose mothers elected to exclusively breastfeed for at least 2 months
* Newborn whose parents / caregivers can be expected to comply with the protocol
* Study explained and written information given
* Informed consent signed

Exclusion Criteria:

* Mother who had antibiotics in the 7 days preceding delivery
* Caesarian section
* Multiple birth
* Congenital illness or malformation that may affect normal growth
* Significant pre-natal and/or post-natal disease
* Newborn participating in another clinical trial

Primary outcomes:
measure: gut maturation : Specific proteins in stools
timeFrame: 3rd day, at 1 week, 2 weeks and 1 month of age
Secondary outcomes:
measure: Growth and gut microbiota
timeFrame: At 1 month and 2 months
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Department of Pediatrics
city: Lyon CEDEX 04
country: France
facility: Service de Réanimation Néonatale et Néonatologie, Hôpital de la Croix Rousse
city: Nancy
country: France
facility: Maternité Régionale, Service de Néonatologie
city: Nantes
country: France
facility: Service de Néonatologie
city: Rouen
country: France
facility: Hôpital Charles Nicolle, Département de Pédiatrie
city: Palaio Faliro
country: Greece
facility: Alexandra Regional General Hospital, Department of Neonatology
state: Athens
Study officials:
affiliation: Service de Réanimation Néonatale et Néonatologie, Hôpital de la Croix Rousse
name: Jean-Charles Pr Picaud
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00519025: Risk Factors for Linezolid Resistance in Staphylococcus Aureus
Official title: Risk Factors for Linezolid Resistance in Staphylococcus Aureus
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Linezolid Resistance
Staphylococcus Aureus
Keywords: Linezolid
Staphylococcus Aureus
Infections
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
First posted: 2007-08-21
Enrollment: 360
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: linezolid resistance to staph aureus

Brief summary: This is a retrospective chart review study. The proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.

Detailed description: This is a retrospective chart review study. The proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed. This research is important because identification of risk factors may allow earlier initiation of appropriate therapy in patients infected with these bacteria. Additionally, we will identify whether horizontal spread is responsible for this increasing trend.

Eligibility criteria: Inclusion Criteria:

* patients with linezolid resistance to staphylococcus aureus

Exclusion Criteria:

* those that don't meet entry criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Brian Potoski, PharmD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04201925: Functional Changes After Upper Blepharoplasty
Official title: Objective and Subjective Functional Outcomes Following Upper Blepharoplasty
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Eyelid Diseases
Keywords: blepharoplasty, visual field
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2019-12-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 50 patient with upper eyelid Dermatochalasis and will undergo upper blepharoblasty procedure.

Brief summary: Upper blepharoplasty is a common eyelid procedure. It associated with visual, cosmetic and functional changes .Investigator will evaluate outcome of this procedure.

Detailed description: baseline and postoperative 1,3,6 and 12 months full ophthalmic examination was done.

Procedure is upper blepharoplasty.

Eligibility criteria: Inclusion Criteria:

• upper eyelid Dermatochalasis

Exclusion Criteria:

* Eyelid diseases
* previous eyelid surgery

Primary outcomes:
measure: visual field changes
timeFrame: 6 months
Secondary outcomes:
measure: corneal topographic changes
timeFrame: 6 months
Other outcomes:
Locations:
city: Abu Dhabi
country: United Arab Emirates
facility: INMC
Study officials:
affiliation: Benha university faculty of medicine
name: TAREK R ELAHAMKY, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05331625: Understanding Quality of Life Among Patients with Cancer Receiving Palliative Care
Official title: Understanding Quality of Life Among Patients with Cancer Receiving Palliative Care
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Cancer
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2022-04-15
Enrollment: 208
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This randomized controlled trial will assess the effects on quality of life of two approaches to symptom management among new patients referred to a palliative care oncology clinic.


Eligibility criteria: Inclusion Criteria:

* Be a new patient at an outpatient palliative care clinic
* Resident of Pennsylvania
* Over 18 years of age

Exclusion Criteria:

* Prior use of certain symptom focused therapies
* Currently pregnant

Primary outcomes:
measure: Quality of Life - McGill Quality of Life Questionnaire
timeFrame: Baseline - 16 weeks
Secondary outcomes:
measure: Feasibility of Accessing Additional Resources for Symptom Management
timeFrame: Baseline - 16 weeks
measure: Acceptability of Accessing Additional Resources for Symptom Management
timeFrame: Baseline - 16 weeks
measure: Symptom Severity
timeFrame: Baseline - 16 weeks
measure: Medication Use
timeFrame: Baseline - 16 weeks
measure: Hospital-Free Days
timeFrame: Baseline - 16 weeks
measure: Mortality
timeFrame: Baseline - 16 weeks
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
References: